Who
Joseph S. McCracken
Director
Company insider
Files Form 4 as: Director, Savara; Director, Lumos Pharma; Director, Kindred Biosciences; Director, Nexvet Biopharma.
In numbers
- Trades disclosed
- 81
- Buys
- 7
- Sells
- 0
- Bought
- $532K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 18 May 2015
- Last trade
- 16 Feb 2026
- Last filed
- 17 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Feb 2026filed 17 Feb 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code M | $3,1801,807 at $1.76 | filing |
| 16 Feb 2026filed 17 Feb 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,807 at $0.00 | filing |
| 16 Feb 2026filed 17 Feb 2026 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,807 at $0.00 | filing |
| 16 Feb 2026filed 17 Feb 2026 | SVRA SavaraBiotechnology | SEC FORM 4 Code M | $3,1801,807 at $1.76 | filing |
| 9 Dec 2025filed 11 Dec 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | SVRA SavaraBiotechnology | SEC FORM 4 Bought | $21K10,000 at $2.08 | filing |
| 12 Dec 2024filed 16 Dec 2024 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —3,345 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —3,328 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —5,684 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —3,431 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code D | —2,910 | filing |
| 12 Dec 2024filed 13 Dec 2024 | Lumos Pharma | SEC FORM 4 Code D | —15,721 | filing |
| 19 Nov 2024filed 20 Nov 2024 | SVRA SavaraBiotechnology | SEC FORM 4 Bought | $59K20,000 at $2.95 | filing |
| 5 Jun 2024filed 7 Jun 2024 | Lumos Pharmaoption or derivative | SEC FORM 4 Code A | —3,328 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | SVRA SavaraBiotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 10 May 2023filed 12 May 2023 | Lumos Pharmaoption or derivative | SEC FORM 4 Code A | —3,345 at $0.00 | filing |
| 13 Dec 2022filed 15 Dec 2022 | SVRA Savaraoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 Nov 2022filed 18 Nov 2022 | Lumos Pharma | SEC FORM 4 Bought | $20K4,000 at $5.03 | filing |
| 25 Aug 2022filed 26 Aug 2022 | Lumos Pharma | SEC FORM 4 Bought | $27K3,170 at $8.60 | filing |
News
No headline names them, or the companies they trade most, lately.